Off-Label Use of Rituximab in a Multipayer Insurance System
نویسندگان
چکیده
منابع مشابه
Off-label use of rituximab in dermatology: pemphigus treatment*
Since its approval in 1997 by the FDA (United States Food and Drug Administration), rituximab has been used for certain B-cell lymphomas and treatment-resistant rheumatoid arthritis. Nevertheless, over the past 14 years, many case reports have demonstrated the efficacy of off-label rituximab in several dermatological inflammatory conditions. This study describes two cases of pemphigus vulgaris ...
متن کاملOff-label use of rituximab in refractory pediatric rheumatic diseases: a single-center experience
Introduction Rituximab (RTX) is a chimeric monoclonal antibody directed against the CD20 antigen on the surface of B lymphocytes. It binds to CD20 and causes B cells death by different mechanisms. In what concerns rheumatic diseases, it is only approved for the treatment of rheumatoid arthritis. However, there is growing evidence of its utility in other diseases, including in pediatric patients.
متن کاملOff-label use of rituximab for systemic lupus erythematosus in Europe
OBJECTIVES Rituximab (RTX) is a biological treatment used off-label in patients with systemic lupus erythematosus (SLE). This survey aimed to investigate the off-label use of RTX in Europe and compare the characteristics of patients receiving RTX with those receiving conventional therapy. METHODS Data on patients with SLE receiving RTX were taken from the International Registry for Biologics ...
متن کاملOff-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases.
OBJECTIVES To analyse the safety and efficacy of the off-label use of rituximab in patients with severe, refractory systemic autoimmune diseases. METHODS In 2006, the Study Group on Autoimmune Diseases of the Spanish Society of Internal Medicine created the BIOGEAS project, a multicenter study devoted to collecting data on the use of biological agents in adult patients with systemic autoimmun...
متن کاملOff-label use of vaccines.
This article reviews the off-label recommendations and use of vaccines, and focuses on the differences between the labelled instructions on how to use the vaccine as approved by the regulatory authorities (or "label"1), and the recommendations for use issued by public health advisory bodies at national and international levels. Differences between public health recommendations and the product l...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Oncology Practice
سال: 2011
ISSN: 1554-7477,1935-469X
DOI: 10.1200/jop.2010.000042